Metabolic Risk Following Gestational Diabetes Mellitus

Hospices Civils de Lyon255 enrolled

Overview

Gestational diabetes (GDM) is defined by abnormal glucose tolerance during gestation. This complication occurs in 4-10% and is associated with fetal complications and macrosomia. In addition, women with GDM have an increased risk to develop type 2 diabetes after delivery. Despite recommendations, it is difficult to follow-up all women with GDM during the postpartum period due to high numbers of subjects that exceed usual healthcare resources. It is therefore necessary to focus clinical attention toward women at high risk of type 2 diabetes in order to set adequate preventive strategies.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

255

Conditions

Gestational Diabetes

Interventions

Blood sampling and OGTTOTHER

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women aged over 18years old * Women with the criteria of GDM during pregnancy at 21-35 weeks of gestation (one situation): * After a 75g Oral Glucose Tolerance Test (OGTT - WHO criteria) with blood glucose (BG) values at T60≥180mg/dl and/or T120≥153mg/dl * An O. Sullivan test following a 100g oral glucose load with at least two pathological values (T60 ≥ 180mg/dl and/or T120 ≥ 155mg/dl and/or T180 ≥ 140mg/dl) * With a fasting BG value ≥92mg/dl * Women with signed informed consent Exclusion Criteria: * Women aged less than 18years old * Women with pregestational type 2 diabetes * Women without signed informed consent * Women who does not read and/or understand french language * Women not affiliated to the health care system * Women with recent infection (\<1month) and/or on steroids or anti-inflammatory drugs. * Women with chronic diseases * Women with a disable state * Women with normal glucose tolerance * Women already incorporated in another clinical study that could interfere with the present study

Locations (7)

Hospices Civils de Lyon - Hôpital Femme-Mère-Enfant - Service de gynécologie obstétrique

Bron, France

CHU Clermont-Ferrand - Hôpital Gabriel Montpied - Service d'endocrinologie

Clermont-Ferrand, France

Centre Hospitalier de Givors - Hôpital de Montgelas - Service de médicine 8

Givors, France

Outcomes

Primary Outcomes

Metabolic index value

The primary objective relies on Receiver Operating Characteristic (ROC) curves of metabolic index values using peripheral markers during gestation : C-Reactive Protein ultrasensitive (CRPus), malonaldehyde (MDA) and adiponectin (index = (CRP + MDA)/adiponectin) to detect an abnormal glucose tolerance at 3 months (+/- 15 days) after delivery (M3) during a 75g oral glucose tolerance test (T0\>110mg/dl and/or T120 \>145mg/dl). The rationale for the index relies on lower adiponectin values high CRPus levels and MDA values during insulin resistance chronic inflammatory status and oxidative stress.

Time frame: 3 months after delivery (+/- 15 days)

Secondary Outcomes

Prevalence of abnormal glucose tolerance in women with GDM

Time frame: 3 months (+/- 15 days) following delivery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.